Flashpoint Therapeutics Celebrates Founder Professor Chad A. Mirkin’s Selection for the 2027 ACS Priestley Medal
Flashpoint Therapeutics, a biotechnology company focused on advancing next-generation nanomedicines, has announced that its founder, Professor Chad A. Mirkin, has been named the recipient of the 2027 Priestley Medal, the highest honor awarded by the American Chemical Society (ACS). The prestigious recognition celebrates Mirkin’s decades of groundbreaking contributions to chemistry, nanotechnology, and materials science, as well as his lasting impact on biomedical research and innovation.
The Priestley Medal is widely regarded as the most distinguished award presented by the American Chemical Society and recognizes individuals whose scientific achievements have fundamentally advanced the field of chemistry. Mirkin’s selection acknowledges not only his pioneering discoveries in nanoscience and supramolecular chemistry but also his influential role in translating scientific breakthroughs into technologies with broad applications in medicine, diagnostics, materials engineering, and biotechnology.
For Flashpoint Therapeutics, the announcement is particularly meaningful because the company’s scientific platform is built upon one of Mirkin’s most influential discoveries—spherical nucleic acids (SNAs). This innovative class of nanomaterials serves as the foundation for Flashpoint’s pipeline of investigational nucleic acid therapeutics designed to address diseases with significant unmet medical needs.
The recognition underscores both Mirkin’s scientific legacy and the growing importance of nanotechnology as a transformative force in modern medicine.
Recognizing Excellence in Chemistry
The Priestley Medal represents the American Chemical Society’s highest distinction and has been awarded annually since its establishment in 1922.
Named after the renowned chemist Joseph Priestley, whose work contributed significantly to the discovery of oxygen and the advancement of modern chemistry, the award honors individuals whose careers have demonstrated exceptional service and lasting contributions to the chemical sciences.
Recipients of the Priestley Medal have historically included many of the world’s most influential chemists, with the list of previous honorees featuring 24 Nobel Prize winners alongside numerous pioneers whose discoveries have shaped modern science.
Professor Mirkin will formally receive the medal during the American Chemical Society Spring 2027 Meeting, scheduled to take place in New Orleans.
His selection places him among an elite group of scientists whose work has had a profound and enduring impact across multiple scientific disciplines.
A Career Dedicated to Scientific Innovation
Over a career spanning more than three decades, Professor Mirkin has become internationally recognized as one of the leading figures in nanotechnology, nanoscience, and supramolecular chemistry.
His research has fundamentally changed how scientists design, synthesize, manipulate, and apply nanoscale materials.
Rather than viewing nanoparticles merely as passive materials, Mirkin’s work demonstrated that carefully engineered nanostructures could possess unique chemical, biological, and physical properties that open entirely new possibilities for medicine, diagnostics, electronics, and advanced manufacturing.
His discoveries have helped establish nanotechnology as one of the most rapidly advancing scientific disciplines of the twenty-first century.
Today, his research continues to influence scientists working across chemistry, medicine, engineering, biology, and materials science around the world.
The Discovery of Spherical Nucleic Acids
Among Professor Mirkin’s many scientific achievements, perhaps none has had greater impact on biotechnology than the invention of spherical nucleic acids (SNAs).
SNAs represent an entirely new class of nanomaterials in which densely arranged nucleic acids are organized around a nanoparticle core.
Unlike conventional linear nucleic acids, SNAs exhibit unique biological properties that enable them to interact with cells in fundamentally different ways.
Researchers have demonstrated that these structures can enter cells efficiently without requiring many of the delivery technologies traditionally used for nucleic acid therapeutics.
This distinctive capability has generated significant interest across pharmaceutical research, where delivery remains one of the major challenges for RNA- and DNA-based medicines.
The discovery has created opportunities for developing therapies capable of modulating gene expression while potentially improving delivery efficiency and therapeutic effectiveness.
Foundation of Flashpoint Therapeutics
Flashpoint Therapeutics was established to build upon Professor Mirkin’s pioneering work and translate spherical nucleic acid technology into innovative therapeutic products.
The company’s research focuses on developing nanomedicines that utilize SNA technology to deliver nucleic acid therapeutics targeting diseases that remain difficult to treat using conventional approaches.
By leveraging the unique biological behavior of SNAs, Flashpoint aims to create next-generation medicines capable of reaching cellular targets more effectively while advancing precision medicine strategies.
The company’s scientific platform directly reflects decades of foundational research conducted in Professor Mirkin’s laboratory.
His discoveries continue to serve as the basis for Flashpoint’s efforts to develop transformative therapies for patients with serious diseases.
Broad Contributions to Nanotechnology
Beyond spherical nucleic acids, Professor Mirkin has contributed extensively to numerous areas of nanoscience and nanotechnology.
His research has led to the creation of entirely new classes of nanomaterials while advancing understanding of how nanoscale structures can be designed for specific biological, chemical, and engineering applications.
These innovations have influenced fields including:
- Drug delivery
- Molecular diagnostics
- Biosensing
- Materials science
- Chemical engineering
- Precision medicine
- Biomedical imaging
Many technologies developed through his research have progressed beyond academic laboratories into commercial products and clinical development programs.
His work has therefore helped bridge the gap between fundamental scientific discovery and practical healthcare innovation.
Academic Leadership at Northwestern University
Professor Mirkin holds numerous academic appointments at Northwestern University, reflecting the interdisciplinary nature of his research.
He serves as:
- George B. Rathmann Professor of Chemistry
- Professor of Medicine (Hematology and Oncology)
- Professor of Materials Science and Engineering
- Professor of Biomedical Engineering
- Professor of Chemical and Biological Engineering
His appointments span several schools within the university, including:
- Weinberg College of Arts and Sciences
- Feinberg School of Medicine
- McCormick School of Engineering
In addition, he serves as Director of Northwestern’s International Institute for Nanotechnology, an internationally recognized research center dedicated to advancing nanoscale science and technology.
These leadership roles have allowed him to foster collaboration among scientists from diverse disciplines while training future generations of researchers.
Mirkin Reflects on the Honor
Commenting on the award, Professor Mirkin described the Priestley Medal as one of the highest distinctions a chemist can receive.
He noted that the list of previous recipients includes many of the most influential scientific figures of the past century, making the recognition especially meaningful.
Mirkin explained that the award also acknowledges decades of collaborative research in nanochemistry, including efforts to develop spherical nucleic acids as a platform capable of enabling next-generation therapies that could ultimately provide substantial benefits for patients.
His remarks reflect the translational philosophy that has characterized much of his career—using advances in chemistry not only to expand scientific knowledge but also to improve human health.
Flashpoint Highlights Scientific Legacy
Barry Labinger, Chief Executive Officer of Flashpoint Therapeutics, congratulated Professor Mirkin on receiving the prestigious honor.
Labinger described Mirkin as a visionary scientist whose pioneering work in nanotechnology has transformed the field of targeted therapeutics.
He emphasized that the invention of spherical nucleic acids fundamentally reshaped how researchers approach nucleic acid medicine and created opportunities for developing highly targeted treatments across numerous disease areas.
According to Labinger, Flashpoint is proud to build upon Mirkin’s scientific foundation as the company continues advancing innovative nanomedicines intended to improve outcomes for patients.
He noted that Mirkin’s discoveries remain central to the organization’s mission of translating cutting-edge nanoscience into meaningful therapeutic advances.
An Extraordinary Record of Achievement
Professor Mirkin’s scientific accomplishments extend well beyond individual discoveries.
Over the course of his career, he has:
- Authored more than 940 scientific publications
- Filed over 1,470 patent applications worldwide
- Received more than 250 scientific honors and awards
These achievements reflect both exceptional research productivity and a sustained commitment to innovation.
His publications have been widely cited by scientists around the world, influencing multiple disciplines and contributing to ongoing advances in chemistry, medicine, materials science, and nanotechnology.
The extensive patent portfolio further demonstrates his emphasis on translating laboratory discoveries into technologies capable of benefiting society.
Entrepreneurial Leadership
In addition to his academic accomplishments, Professor Mirkin has played a significant role as a scientific entrepreneur.
Throughout his career, he has founded 11 companies dedicated to commercializing technologies developed through his research.
These ventures have helped accelerate the translation of scientific discoveries into products spanning diagnostics, therapeutics, nanotechnology, and advanced materials.
Flashpoint Therapeutics represents one of these entrepreneurial efforts, serving as a vehicle for advancing spherical nucleic acid-based medicines from laboratory research toward clinical application.
His ability to combine academic excellence with commercial innovation has distinguished him as one of the leading scientific entrepreneurs of his generation.
Professor Chad A. Mirkin’s selection as the recipient of the 2027 Priestley Medal recognizes a career that has fundamentally reshaped the fields of chemistry, nanotechnology, and biomedical innovation. Through pioneering discoveries such as spherical nucleic acids, he has expanded scientific understanding of nanoscale materials while creating new opportunities for developing next-generation therapeutics capable of addressing complex diseases.
For Flashpoint Therapeutics, the award highlights the scientific foundation upon which the company continues to build its pipeline of innovative nanomedicines. As researchers increasingly explore the therapeutic potential of nucleic acid technologies and precision medicine, Mirkin’s work remains at the forefront of efforts to translate advances in chemistry into meaningful improvements in patient care. His recognition by the American Chemical Society not only celebrates decades of extraordinary scientific achievement but also underscores the continuing impact of his discoveries on the future of medicine, biotechnology, and global healthcare innovation.
About Flashpoint Therapeutics
Flashpoint Therapeutics is a clinical-stage biotechnology company developing a new class of precision-engineered structural nanomedicines. Our platform enables the creation of targeted therapies that co-deliver optimized combinations of therapeutic components directly to individual cells, enhancing drug delivery, stability, potency, and safety.
This modular approach supports a broad range of therapies, encompassing modalities like mRNA, siRNA, DNA, proteins, and CRISPR. The company’s proprietary discovery platform is founded on nanotechnology research developed over the past decade at the laboratory of Prof. Chad Mirkin, Director of the International Institute for Nanotechnology at Northwestern University.
Through strategic licensing and acquisition transactions with Northwestern University, Holden Pharmaceuticals, and Exicure, Flashpoint has assembled more than 150 issued patents and patent applications covering nucleic acid, protein, and CRISPR gene editing therapeutics. The company is funded by key investors, including Beta Lab and CS Venture Opportunities Fund.
The company has also established an important partnership with King Abdullah International Medical Research Center (KAIMRC), which will advance the technology platform via the Flashpoint-KAIMRC Center of Excellence in Structural Nanomedicine and clinical trials in Saudi research institutions.